ComplianceOnline

GMP Expectations for Products Used in Early Phase IND Studies

Instructor: Steven S Kuwahara
Product ID: 701009
  • Duration: 75 Min

recorded version

$249.00
1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

$500.00
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556

Email: customercare@complianceonline.com

Read Frequently Asked Questions

This presentation will review the GMP guidance document and discuss how it may be integrated with the recommendations of the guidance documents on CMC requirements.

Description

This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany early stages of Product development.

FDA has issued a guidance document covering GMP requirements for products that will be used in early stage clinical studies. These guidelines are in addition to those that cover the CMC sections for IND submissions at Phase 1. The nature and extent of the GMP activities depend upon the nature of the investigational drug and the extent of the study that is planned. This presentation will review the GMP guidance document and discuss how it may be integrated with the recommendations of the guidance documents on CMC requirements.

Areas Covered in the seminar:

  • Discussion of the elements to be found in the key guidance document for Phase 1 material.
  • What to do at really early stages.
  • What about special IND studies?
  • What about preclinical studies?
  • Varying GMP activities that depend upon the nature of the IND product.
  • Which regulations come into play at different stages of product development.
  • What to do about QC activities such as instrument qualification, method validation, and process validation.

Who will benefit:

This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany early stages of Product development.

  • Regulatory Affairs personnel who coordinate activities for the CMC sections of submissions
  • QA/QC personnel who need to plan work
  • R & D personnel who will contribute data to CMC sections
  • Project managers for product development studies
  • Quality systems auditors
  • Consultants

Instructor Profile:

Steven S. Kuwahara, Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . He has participated in the product development process for small molecule drugs and biologics, and has prepared or reviewed many CMC sections.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
ComplianceOnline Medical Device Summit 2017

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed
    Loading